Atul Verma1. 1. Southlake Heart Rhythm Program, Division of Cardiology, Southlake Regional Health Centre, Newmarket, Ontario, Canada.
Abstract
Background: Ablation for atrial fibrillation (AF) is a widely-accepted treatment for this arrhythmia. Ablation is traditionally reserved for second-line therapy in patients who have failed drug therapy, but it may be ready for first-line treatment. Objective: This article outlines the rationale for using ablation as first-line therapy for AF. Findings: AF increases both morbidity and mortality. Unfortunately, drug-based therapy for AF is very ineffective and may contribute adversely to both patient morbidity and mortality. Ablation addresses the root causes of AF and thus may be curative. The technique for ablation has become quite consistent and the outcomes better than those with drug therapy. The complication risk is also acceptably low. There is even preliminary evidence to suggest that AF ablation is superior as first-line treatment compared to drugs. Conclusion: AF ablation is rapidly evolving towards becoming first-line therapy for some patients with this debilitating arrhythmia.
Background: Ablation for atrial fibrillation (AF) is a widely-accepted treatment for this arrhythmia. Ablation is traditionally reserved for second-line therapy in patients who have failed drug therapy, but it may be ready for first-line treatment. Objective: This article outlines the rationale for using ablation as first-line therapy for AF. Findings: AF increases both morbidity and mortality. Unfortunately, drug-based therapy for AF is very ineffective and may contribute adversely to both patient morbidity and mortality. Ablation addresses the root causes of AF and thus may be curative. The technique for ablation has become quite consistent and the outcomes better than those with drug therapy. The complication risk is also acceptably low. There is even preliminary evidence to suggest that AF ablation is superior as first-line treatment compared to drugs. Conclusion:AF ablation is rapidly evolving towards becoming first-line therapy for some patients with this debilitating arrhythmia.
Authors: Hakan Oral; Carlo Pappone; Aman Chugh; Eric Good; Frank Bogun; Frank Pelosi; Eric R Bates; Michael H Lehmann; Gabriele Vicedomini; Giuseppe Augello; Eustachio Agricola; Simone Sala; Vincenzo Santinelli; Fred Morady Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245
Authors: C P Lau; H F Tse; C M Yu; W S Teo; R Kam; K S Ng; S S Huang; J L Lin; S M Fitts; D A Hettrick; M R Hill Journal: Am J Cardiol Date: 2001-08-15 Impact factor: 2.778
Authors: Mark D O'Neill; Pierre Jaïs; Yoshihide Takahashi; Anders Jönsson; Frédéric Sacher; Mélèze Hocini; Prashanthan Sanders; Thomas Rostock; Martin Rotter; Andrej Pernat; Jacques Clémenty; Michel Haïssaguerre Journal: J Interv Card Electrophysiol Date: 2006-11-14 Impact factor: 1.900